Judith S. Sebolt–Leopold
0000-0002-0351-8505
Publication & Citation Trends
Publications
0 total
Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).
Cited by 0
Semantic Scholar
Abstract 5603: A precision polypharmacology approach to co-target EGFR and PI3 kinase: the power of structure-based drug design to generate therapeutic agents with versatility in multiple combination settings
Cited by 0
Semantic Scholar
Abstract 5248: Identification of a chromatin-remodeling peptide in diffuse midline glioma by immunopeptidomics
Cited by 0
Semantic Scholar
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance OA
Cited by 13
Semantic Scholar
Abstract 1230: MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance
Cited by 1
Semantic Scholar
Abstract C150: Targeted inhibition of homologous recombination and nonhomologous end joining in diffuse intrinsic pontine gliomas to prevent tumor recurrence
Cited by 0
Semantic Scholar
Research Topics
Melanoma and MAPK Pathways
(70)
Colorectal Cancer Treatments and Studies
(29)
Pancreatic and Hepatic Oncology Research
(27)
Advanced Breast Cancer Therapies
(27)
PI3K/AKT/mTOR signaling in cancer
(25)
Affiliations
Cedars-Sinai Medical Center
Gaertner (United States)
Mayo Clinic
University of Auckland
University of California, Los Angeles